  | Rigg, E., Wang, J., Xue, Z., Lunavat, T. R., Liu, G., Hoang, T., Parajuli, H., Han, M., Bjerkvig, R., Nazarov, P. V., Nicot, N., KREIS, S., WURTH-MARGUE, C., TETSI NOMIGNI, M., Utikal, J., Miletic, H., Sundstrøm, T., Ystaas, L. A. R., Li, X., & Thorsen, F. (October 2023). Inhibition of extracellular vesicle-derived miR-146a-5p decreases progression of melanoma brain metastasis via Notch pathway dysregulation in astrocytes. Journal of Extracellular Vesicles, 12 (10), 12363. doi:10.1002/jev2.12363  Peer Reviewed verified by ORBi |
 | GUREGHIAN, V., HERBST, H., KOZAR, I., MIHAJLOVIC, K., Malod-Dognin, N., Ceddia, G., ANGELI, C., WURTH-MARGUE, C., RANDIC, T., PHILIPPIDOU, D., TETSI NOMIGNI, M., HEMEDAN, A., TRANCHEVENT, L.-C., LONGWORTH, J., Bauer, M., BADKAS, A., GAIGNEAUX, A., Muller, A., OSTASZEWSKI, M., ... KREIS, S. (October 2023). A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma. Cancer Gene Therapy, 30 (10), 1330 - 1345. doi:10.1038/s41417-023-00640-z Peer Reviewed verified by ORBi |
 | Bintener, T., PIRES PACHECO, M. I., PHILIPPIDOU, D., MARGUE, C., KISHK, A., Del Mistro, G., Di Leo, L., MOSCARDO GARCIA, M., HALDER, R., SINKKONEN, L., De Zio, D., KREIS, S., Kulms, D., & SAUTER, T. (26 July 2023). Metabolic modelling-based in silico drug target prediction identifies six novel repurposable drugs for melanoma. Cell Death and Disease, 14 (468). doi:10.1038/s41419-023-05955-1 Peer Reviewed verified by ORBi |
 | RANDIC, T., KOZAR, I., MARGUE, C., Utikal, J., & KREIS, S. (29 May 2021). NRAS mutant melanoma: Towards better therapies. Cancer Treatment Reviews, 99. doi:10.1016/j.ctrv.2021.102238 Peer Reviewed verified by ORBi |
 | KOZAR, I., PHILIPPIDOU, D., MARGUE, C., Gay, L., Renne, R., & KREIS, S. (2021). Cross-Linking Ligation and Sequencing of Hybrids (qCLASH) Reveals an Unpredicted miRNA Targetome in Melanoma Cells. Cancers. doi:10.3390/cancers13051096 Peer Reviewed verified by ORBi |
 | KIRCHMEYER, M., SERVAIS, F., GINOLHAC, A., Nazarov, P. V., MARGUE, C., PHILIPPIDOU, D., Nicot, N., BEHRMANN, I., HAAN, C., & KREIS, S. (2020). Systematic transcriptional profiling of responses to STAT1- and STAT3- activating cytokines in different cancer types. Journal of Molecular Biology. doi:10.1016/j.jmb.2020.09.011 Peer Reviewed verified by ORBi |
 | Walbrecq, G., MARGUE, C., BEHRMANN, I., & KREIS, S. (2020). Distinct Cargos of Small Extracellular Vesicles Derived from Hypoxic Cells and Their Effect on Cancer Cells. International Journal of Molecular Sciences. doi:10.3390/ijms21145071 Peer Reviewed verified by ORBi |
 | Walbrecq, G., Lecha, O., GAIGNEAUX, A., Fougeras, M. R., PHILIPPIDOU, D., MARGUE, C., TETSI NOMIGNI, M., Bernardin, F., DITTMAR, G., BEHRMANN, I., & KREIS, S. (2020). Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles. Cancers. doi:10.3390/cancers12030692 Peer Reviewed verified by ORBi |
 | KOZAR, I., MARGUE, C., Rothengatter, S., HAAN, C., & KREIS, S. (15 February 2019). Many ways to resistance: How melanoma cells evade targeted therapies. Biochimica et Biophysica Acta. Reviews on Cancer, 1871 (2), 313-322. doi:10.1016/j.bbcan.2019.02.002 Peer Reviewed verified by ORBi |
 | MARGUE, C., PHILIPPIDOU, D., KOZAR, I., CESI, G., FELTEN, P., Kulms, D., LETELLIER, E., HAAN, C., & KREIS, S. (February 2019). Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. Journal of Experimental and Clinical Cancer Research, 38 (1). doi:10.1186/s13046-019-1038-x Peer Reviewed verified by ORBi |
 | ROLVERING, C., ZIMMER, A. D., GINOLHAC, A., MARGUE, C., KIRCHMEYER, M., SERVAIS, F., Hermanns, H. M., Hergovits, S., Nazarov, P. V., Nicot, N., KREIS, S., HAAN, S., BEHRMANN, I., & HAAN, C. (2018). The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by a-PD-L1 or a-IL6 antibodies. Journal of Leukocyte Biology, 104, 969-985. doi:10.1002/JLB.MA1217-495R Peer Reviewed verified by ORBi |
 | KREIS, S., KOZAR, I., CESI, G., MARGUE, C., & PHILIPPIDOU, D. (2017). Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Biochimica et Biophysica Acta. doi:10.1016/j.bbagen.2017.04.005 Peer Reviewed verified by ORBi |
  | Heulot, M., Chevalier, N., Puyal, J., MARGUE, C., Michel, S., KREIS, S., Kulms, D., Barras, D., Nahimana, A., & Widmann, C. (27 September 2016). The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner. Oncotarget, 7 (39). doi:10.18632/oncotarget.11841 Peer Reviewed verified by ORBi |
 | CESI, G., WALBRECQ, G., MARGUE, C., & KREIS, S. (10 June 2016). Transferring intercellular signals and traits between cancer cells: extracellular vesicles as "homing pigeons". Cell Communication and Signaling, 14 (1), 13. doi:10.1186/s12964-016-0136-z Peer Reviewed verified by ORBi |
 | BEHRMANN, I., MARGUE, C., & KREIS, S. (2015). Circulating microRNAs as candidate biomarkers for the surveillance of melanoma patients. EBioMedicine. doi:10.1016/j.ebiom.2015.07.015 Peer Reviewed verified by ORBi |
 | MARGUE, C., REINSBACH, S., PHILIPPIDOU, D., BEAUME, N., Walters, C., SCHNEIDER, J., Nashan, D., BEHRMANN, I., & KREIS, S. (2015). Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget, 6 (14), 12110-27. doi:10.18632/oncotarget.3661 Peer Reviewed verified by ORBi |
 | MARGUE, C., PHILIPPIDOU, D., REINSBACH, S., SCHMITT, M., BEHRMANN, I., & KREIS, S. (05 September 2013). New Target Genes of MITF-Induced microRNA-211 Contribute to Melanoma Cell Invasion. PLoS ONE, 8 (9). doi:10.1371/journal.pone.0073473 Peer Reviewed verified by ORBi |
 | Schmitt, M., MARGUE, C., BEHRMANN, I., & KREIS, S. (2012). MiRNA-29: A microRNA family with tumor-suppressing and immune-modulating properties. Current Molecular Medicine, 13 (4), 572-585. doi:10.2174/1566524011313040009 Peer Reviewed verified by ORBi |
 | Schmitt, M. J., PHILIPPIDOU, D., REINSBACH, S., MARGUE, C., WIENECKE-BALDACCHINO, A., Nashan, D., BEHRMANN, I., & KREIS, S. (2012). Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Communication and Signaling, 10. doi:10.1186/1478-811X-10-41 Peer Reviewed verified by ORBi |
 | PHILIPPIDOU, D., SCHMITT, M., Moser, D., MARGUE, C., Nazarov, P. V., Muller, A., Vallar, L., Nashan, D., BEHRMANN, I., & KREIS, S. (2010). Signatures of MicroRNAs and selected MicroRNA target genes in human melanoma. Cancer Research, 70 (10), 4163-4173. doi:10.1158/0008-5472.CAN-09-4512 Peer Reviewed verified by ORBi |
| MARGUE, C., & KREIS, S. (2010). IL-24: Physiological and supraphysiological effects on normal and malignant cells. Current Medicinal Chemistry, 17 (29), 3318-3326. doi:10.2174/092986710793176311 Peer Reviewed verified by ORBi |
 | Vanhoorelbeke, K., De Meyer, S. F., Pareyn, I., Melchior, C., Plançon, S., WURTH-MARGUE, C., Pradier, O., Fondu, P., Kieffer, N., Springer, T. A., & Deckmyn, H. (29 May 2009). The novel S527F mutation in the integrin beta3 chain induces a high affinity alphaIIbbeta3 receptor by hindering adoption of the bent conformation. Journal of Biological Chemistry, 284 (22), 14914 - 14920. doi:10.1074/jbc.M809167200 Peer Reviewed verified by ORBi |
 | KREIS, S., PHILIPPIDOU, D., MARGUE, C., & BEHRMANN, I. (10 May 2008). IL-24: a classic cytokine and/or a potential cure for cancer? Journal of Cellular and Molecular Medicine, 12 (6A), 2505-2510. doi:10.1111/j.1582-4934.2008.00372.x Peer reviewed |
HAAN, S., MARGUE, C., Engrand, A., ROLVERING, C., Schmitz-Van de Leur, H., Heinrich, P. C., BEHRMANN, I., & HAAN, C. (2008). Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. Journal of Immunology, 180 (2), 998-1007. doi:10.4049/jimmunol.180.2.998 Peer Reviewed verified by ORBi |
 | KREIS, S., PHILIPPIDOU, D., MARGUE, C., ROLVERING, C., HAAN, C., Dumoutier, L., Renauld, J.-C., & BEHRMANN, I. (2007). Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS ONE, 2 (12), 1300. doi:10.1371/journal.pone.0001300 Peer Reviewed verified by ORBi |
SCHMITZ, M., Grignard, G., MARGUE, C., Dippel, W., Capesius, C., Mossong, J., Nathan, M., Giacchi, S., Scheiden, R., & Kieffer, N. (2007). Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. International Journal of Cancer, 120 (6), 1284-92. doi:10.1002/ijc.22359 Peer Reviewed verified by ORBi |
 | HAAN, C., KREIS, S., MARGUE, C., & BEHRMANN, I. (November 2006). Jaks and cytokine receptors - an intimate relationship. Biochemical Pharmacology, 72 (11), 1538-46. doi:10.1016/j.bcp.2006.04.013 Peer Reviewed verified by ORBi |
Kieffer, N., SCHMITZ, M., Plançon, S., WURTH-MARGUE, C., Huselstein, F., Grignard, G., Dippel, W., Nathan, M., Giacchi, S., & Scheiden, R. (June 2005). ILK as a potential marker gene to ascertain specific adenocarcinoma cell mRNA isolation from frozen prostate biopsy tissue sections. International Journal of Oncology, 26 (6), 1549 - 1558. doi:10.3892/ijo.26.6.1549 Peer Reviewed verified by ORBi |
Pecheur, I., Peyruchaud, O., Serre, C.-M., Guglielmi, J., Voland, C., Bourre, F., MARGUE, C., Cohen-Solal, M., Buffet, A., Kieffer, N., & Clezardin, P. (2002). Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB Journal, 16 (10), 1266-8. doi:10.1096/fj.01-0911fje Peer Reviewed verified by ORBi |
MARGUE, C., Bernasconi, M., Barr, F., & Schäfer, B. (08 June 2000). Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene, 19 (25), 2921. doi:10.1038/sj.onc.1203607 Peer Reviewed verified by ORBi |
Filser, N., MARGUE, C., & Richter, C. (1997). Quantification of wild-type mitochondrial DNA and its 4.8-kb deletion in rat organs. Biochemical and Biophysical Research Communications, 233 (1), 102-7. doi:10.1006/bbrc.1997.6409 Peer reviewed |
